161 related articles for article (PubMed ID: 37904179)
1. Identification of RECK as a protective prognostic indicator and a tumor suppressor through regulation of the ERK/MAPK signaling pathway in gastric cancer.
Qi F; Wang Y; Yu B; Li F
J Transl Med; 2023 Oct; 21(1):766. PubMed ID: 37904179
[TBL] [Abstract][Full Text] [Related]
2. MiR-374b-5p suppresses RECK expression and promotes gastric cancer cell invasion and metastasis.
Xie J; Tan ZH; Tang X; Mo MS; Liu YP; Gan RL; Li Y; Zhang L; Li GQ
World J Gastroenterol; 2014 Dec; 20(46):17439-47. PubMed ID: 25516656
[TBL] [Abstract][Full Text] [Related]
3. Exosomal miR-182 regulates the effect of RECK on gallbladder cancer.
Zheng H; Wang JJ; Zhao LJ; Yang XR; Yu YL
World J Gastroenterol; 2020 Mar; 26(9):933-946. PubMed ID: 32206004
[TBL] [Abstract][Full Text] [Related]
4. Attenuated expression and function of the RECK tumor suppressor under hypoxic conditions is mediated by the MAPK signaling pathways.
Jeon HW; Lee KJ; Lee SH; Kim WH; Lee YM
Arch Pharm Res; 2011 Jan; 34(1):137-45. PubMed ID: 21468925
[TBL] [Abstract][Full Text] [Related]
5. MiR-25 promotes gastric cancer cells growth and motility by targeting RECK.
Zhao H; Wang Y; Yang L; Jiang R; Li W
Mol Cell Biochem; 2014 Jan; 385(1-2):207-13. PubMed ID: 24078004
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases.
Namwat N; Puetkasichonpasutha J; Loilome W; Yongvanit P; Techasen A; Puapairoj A; Sripa B; Tassaneeyakul W; Khuntikeo N; Wongkham S
J Gastroenterol; 2011 May; 46(5):664-75. PubMed ID: 21076843
[TBL] [Abstract][Full Text] [Related]
7. Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer.
Song SY; Son HJ; Nam E; Rhee JC; Park C
Eur J Cancer; 2006 Jan; 42(1):101-8. PubMed ID: 16324834
[TBL] [Abstract][Full Text] [Related]
8. Reversion-inducing cysteine-rich protein with Kazal motifs and its regulation by glycogen synthase kinase 3 signaling in oral cancer.
Pramanik KK; Singh AK; Alam M; Kashyap T; Mishra P; Panda AK; Dey RK; Rana A; Nagini S; Mishra R
Tumour Biol; 2016 Nov; 37(11):15253-15264. PubMed ID: 27696293
[TBL] [Abstract][Full Text] [Related]
9. RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation.
Hong KJ; Wu DC; Cheng KH; Chen LT; Hung WC
J Cell Physiol; 2014 Feb; 229(2):191-201. PubMed ID: 23881612
[TBL] [Abstract][Full Text] [Related]
10. RECKing MMP: relevance of reversion-inducing cysteine-rich protein with kazal motifs as a prognostic marker and therapeutic target for cancer (a review).
Nagini S
Anticancer Agents Med Chem; 2012 Sep; 12(7):718-25. PubMed ID: 22292753
[TBL] [Abstract][Full Text] [Related]
11. Reversion-inducing cysteine-rich protein with Kazal motifs interferes with epidermal growth factor receptor signaling.
Kitajima S; Miki T; Takegami Y; Kido Y; Noda M; Hara E; Shamma A; Takahashi C
Oncogene; 2011 Feb; 30(6):737-50. PubMed ID: 20890302
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Non-Small Cell Lung Cancer Growth and Metastasis by a Novel Small Molecular Activator of RECK.
Shen J; Wang B; Zhang T; Zhu N; Wang Z; Jin J; He Y; Hu M
Cell Physiol Biochem; 2018; 45(5):1807-1817. PubMed ID: 29510387
[TBL] [Abstract][Full Text] [Related]
13. Dephosphorylation-induced EZH2 activation mediated RECK downregulation by ERK1/2 signaling.
Ning S; Ma X
J Cell Physiol; 2019 Aug; 234(10):19010-19018. PubMed ID: 30912166
[TBL] [Abstract][Full Text] [Related]
14. m
Xie JW; Huang XB; Chen QY; Ma YB; Zhao YJ; Liu LC; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Zheng CH; Huang CM; Li P
Mol Cancer; 2020 Jul; 19(1):114. PubMed ID: 32650804
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of RECK in pathological outcome-dependent buccal mucosa squamous cell carcinoma.
Chen HC; Tseng YK; Shu CW; Fu TY; Liou HH; Huang CH; Chen CC; Wang JS; Wu PC; Ger LP; Hung WC; Liu PF
Oral Dis; 2020 Jan; 26(1):62-71. PubMed ID: 31618798
[TBL] [Abstract][Full Text] [Related]
16. RECK inhibits cervical cancer cell migration and invasion by promoting p53 signaling pathway.
Liu Y; Li L; Liu Y; Geng P; Li G; Yang Y; Song H
J Cell Biochem; 2018 Apr; 119(4):3058-3066. PubMed ID: 29064588
[TBL] [Abstract][Full Text] [Related]
17. microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs.
Pan Y; Liang H; Chen W; Zhang H; Wang N; Wang F; Zhang S; Liu Y; Zhao C; Yan X; Zhang J; Zhang CY; Gu H; Zen K; Chen X
RNA Biol; 2015; 12(3):276-89. PubMed ID: 25826661
[TBL] [Abstract][Full Text] [Related]
18. [Expression of MT1-MMP and RECK protein in human gastric carcinoma].
Shen B; Zheng MQ; Xu XY; Mo FG; Zhang T; Feng JF
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):364-7. PubMed ID: 22338226
[TBL] [Abstract][Full Text] [Related]
19. miR-544a Stimulates endometrial carcinoma growth via targeted inhibition of reversion-inducing cysteine-rich protein with Kazal motifs.
Zheng WP; Meng FL; Wang LY
Mol Cell Probes; 2020 Oct; 53():101572. PubMed ID: 32525042
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK).
Yoshida D; Nomura R; Teramoto A
J Neurooncol; 2008 Sep; 89(2):141-50. PubMed ID: 18493720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
